⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8938159 | 0.74 | ALDH1A1 (0.43) | — | |
| SCHEMBL30174455 | 0.65 | CCR1 (0.44) | — | |
| SCHEMBL156284 | 0.65 | — | — | |
| SCHEMBL881753 | 0.65 | — | — | |
| SCHEMBL451303 | 0.62 | — | — | |
| SCHEMBL23442 | 0.62 | — | — | |
| SCHEMBL24037551 | 0.61 | MAPT (0.36) | — | |
| SCHEMBL3233384 | 0.61 | EGFR (0.38) | — | |
| SCHEMBL17673782 | 0.60 | NOS1 (0.47) | — | |
| SCHEMBL2042187 | 0.60 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9365566-B2 | Cinnoline derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-06-14 | — | — | US | claimed |
| EP-3004060-A1 | COMPOUNDS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2016-04-13 | — | — | EP | claimed |
| US-20150038510-A1 | CINNOLINE DERIVATIVES | TAKEDA CALIFORNIA, INC. | 2015-02-05 | — | — | US | claimed |
| US-20140357612-A1 | COMPOUNDS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2014-12-04 | — | — | US | claimed |
| WO-2014194127-A1 | COMPOUNDS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2014-12-04 | — | — | WO | claimed |
| US-8309735-B2 | Heterocyclic compounds for the inhibition of integrins and use thereof | SHIRE ORPHAN THERAPIES GMBH (DE) | 2012-11-13 | — | — | US | claimed |
| US-20090203745-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF INTEGRINS AND USE THEREOF | JERINI AG (DE) | 2009-08-13 | — | — | US | claimed |
| US-20090104116-A1 | COMPOUNDS FOR THE INHIBITION OF INTEGRINS AND USE THEREOF | JERINI AG (DE) | 2009-04-23 | — | — | US | claimed |
| EP-2024357-A2 | NEW HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF INTEGRINS AND USE THEREOF | Jereni AG (DE) | 2009-02-18 | — | — | EP | claimed |
| EP-1979342-A1 | COMPOUNDS FOR THE INHIBITION OF INTEGRINS AND USE THEREOF | Jerini AG (DE) | 2008-10-15 | — | — | EP | claimed |
| WO-2007131764-A2 | NEW HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF INTEGRINS AND USE THEREOF | JERINI AG (DE) | 2007-11-22 | — | — | WO | claimed |
| WO-2007088041-A1 | COMPOUNDS FOR THE INHIBITION OF INTEGRINS AND USE THEREOF | JERINI AG (DE) | 2007-08-09 | — | — | WO | claimed |
| EP-1385848-A2 | PHTALAZINONES DERIVATIVES USEFUL AS PDE4/7 INHIBITORS | ALTANA Pharma AG (DE) | 2004-02-04 | — | — | EP | claimed |
| WO-2002085906-A2 | PHTHALAZINONES DERIVATIVES USEFUL AS PDE4/7 INHIBITORS | ALTANA PHARMA AG (DE) | 2002-10-31 | — | — | WO | claimed |
| US-20230331725-A1 | COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS, INC. | 2023-10-19 | — | — | US | disclosed |
| US-11780839-B2 | Compounds for treating Huntington's disease | PTC THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| EP-3969446-B1 | COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS INC (US) | 2023-09-27 | — | — | EP | disclosed |
| US-7084278-B2 | Process for production of optically active compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-08-01 | — | — | US | disclosed |
| US-20050107433-A1 | Process for production of optically active compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-05-19 | — | — | US | disclosed |
| EP-1489070-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE COMPOUNDS | Takeda Chemical Industries, Ltd. (JP) | 2004-12-22 | — | — | EP | disclosed |